Kidney International Reports最新文献

{"title":"Response to the Letter to the Editor Entitled “IMPACT CKD – All Roads Must Not Lead to Dialysis”","authors":"Juan J. Garcia Sanchez , Stacey Priest , Hannah Guiang , Anthony Zara , David C. Wheeler , Ana F. Moura , Charlotte Johnston-Webber , Jieling Chen","doi":"10.1016/j.ekir.2025.06.026","DOIUrl":"10.1016/j.ekir.2025.06.026","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2886-2887"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Evaluation of System-Wide Implementation of Kidney Supportive Care","authors":"Lisa L. Brady ,&nbsp;Annie Hutton ,&nbsp;Jeremy R. Chapman ,&nbsp;Gerard Duck ,&nbsp;Tessa Gastrell ,&nbsp;Angela Makris ,&nbsp;Dennis McCarthy ,&nbsp;Michael Noel ,&nbsp;Liz Hay ,&nbsp;Peter Choi","doi":"10.1016/j.ekir.2025.05.022","DOIUrl":"10.1016/j.ekir.2025.05.022","url":null,"abstract":"<div><h3>Introduction</h3><div>This evaluation explored the economic value of kidney supportive care (KSC) in patients with end-stage kidney disease (ESKD) receiving dialysis or conservative management for ESKD in the public health system of New South Wales, Australia.</div></div><div><h3>Methods</h3><div>Deidentified patient-level data were extracted from a linked dataset of admitted and nonadmitted patient data, emergency department episodes, and death registrations. Data between 1 July 2015 and 30 June 2019 were compared with usual treatment prior to statewide KSC implementation in the 2015-2016 financial years. A cost-benefit analysis model estimated the current economic value of KSC (1 July 2015 to 30 June 2019) and projected value to 30 June 2030 under different scenarios.</div></div><div><h3>Results</h3><div>The proportion of all patients with ESKD receiving KSC increased from 5% in 2015 to 2016 (<em>n</em> = 443) to 16% by 2018 to 2019. Over this period, KSC was estimated to increase survival by 3 to 21 weeks, depending on patient characteristics. Projections showed that continued delivery of KSC, with ESKD treatment modality patterns and costs remaining stable, would deliver a net economic benefit of A$ 109 million through avoided costs of care and return on investment (ROI) of 212%. When adjusted to include survival improvements attributable to KSC, the net economic benefit increased to A$ 275 million (ROI: 535%).</div></div><div><h3>Conclusion</h3><div>Economic evaluation of the statewide KSC service showed survival benefits and a net economic benefit 4 years after implementation. Net economic value over 10 years was estimated at A$ 275 million, which would increase with greater participation of patients with ESKD suitable for KSC.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2597-2607"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Treatment for Acute Interstitial Nephritis","authors":"Yalin Yu ,&nbsp;Erik Biros ,&nbsp;Xiao Chang ,&nbsp;Andrew J. Mallett","doi":"10.1016/j.ekir.2025.05.009","DOIUrl":"10.1016/j.ekir.2025.05.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Acute interstitial nephritis (AIN) is a common cause of acute kidney injury. It is characterized by tubular inflammation with eosinophils histologically. The mainstay treatment for AIN includes early diagnosis; underlying infection or systemic disease treatment; cessation of the offending agent; and corticosteroid therapy, when indicated. This systematic review aims to evaluate the efficacy and safety of pharmacotherapy treatments for AIN by assessing treatment outcomes and adverse effects.</div></div><div><h3>Methods</h3><div>PubMed, Embase, Cochrane Library, and other major databases were systematically searched in June 2024 after registration with the International Prospective Register of Systematic Reviews. Manual searches of the references in relevant articles were conducted. Studies focusing on the treatment of AIN cases that were diagnosed histologically were included. A fixed-effects meta-analysis and meta-regression were performed using Stata SE 16.</div></div><div><h3>Results</h3><div>A total of 3597 articles were eligible for screening. Twenty-three articles were included in the systematic review. There were 3 randomized controlled trials, 4 case series, and 16 retrospective cohort studies. Corticosteroids were the primary treatment in most of the studies, with 1 study evaluating the use of mycophenolate mofetil (MMF) in steroid-refractory patients. A meta-analysis of 3 studies showed that prednisolone use improved renal outcomes. There was significant variability across studies in dosing, treatment duration, and timing of initiation. Adverse events associated with corticosteroids were likely underreported.</div></div><div><h3>Conclusion</h3><div>Consistent evidence supporting the use of corticosteroids for treating AIN needs to be more comprehensive. There needs to be a clear consensus on the optimal treatment regimen. High-quality randomized controlled trials are required to help establish evidence-based guidelines for treating AIN.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2575-2584"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment With Avacopan in ANCA–Associated Vasculitis With Kidney Involvement","authors":"Duvuru Geetha ,&nbsp;Frank B. Cortazar ,&nbsp;Annette Bruchfeld ,&nbsp;Andreas Kronbichler ,&nbsp;Alexandre Karras ,&nbsp;Georges N. Nakhoul ,&nbsp;Peter A. Merkel ,&nbsp;Sarah Bray ,&nbsp;Alana M. Bozeman ,&nbsp;David R.W. Jayne","doi":"10.1016/j.ekir.2025.05.041","DOIUrl":"10.1016/j.ekir.2025.05.041","url":null,"abstract":"<div><h3>Introduction</h3><div>Kidney disease impacts long-term outcomes of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This <em>post hoc</em> analysis evaluated the effect of avacopan in a subgroup of patients with GPA or MPA and kidney involvement at baseline from the ADVOCATE trial.</div></div><div><h3>Methods</h3><div>The analysis included a study population of 268 patients (of 330 patients, 81.2%). Key efficacy outcomes were remission at week 26, sustained remission at week 52, and relapse after remission through week 52. Changes in estimated glomerular filtration rate (eGFR) were analyzed overall and stratified by baseline eGFR categories (≥ 90, 60–89, 45–59, 30–44, and 15–29 ml/min per 1.73 m²). Additional outcomes were changes in albuminuria and hematuria, glucocorticoid (GC) use, glucocorticoid toxicity index (GTI), and safety.</div></div><div><h3>Results</h3><div>Remission at week 26 and sustained remission at week 52, respectively, were respectively achieved by 99 of 134 (73.9%) and 91 of 134 (67.9%) patients in the avacopan group and 95 of 134 (70.9%) and 76 of 134 (56.7%) in the prednisone taper group. Relapse rate after remission was lower in the avacopan than in the prednisone taper group (9.4% vs. 20.9%; hazard ratio [95% confidence interval, CI]: 0.43 [0.22–0.85]). Recovery of kidney function, speed of reduction in albuminuria and hematuria, and changes in GTI favored the avacopan group. No new safety issues were reported for this subset of patients.</div></div><div><h3>Conclusion</h3><div>In patients with GPA or MPA with kidney involvement, treatment with an avacopan regimen compared with a prednisone taper regimen achieved similar rates of remission, improved recovery of kidney function, led to faster reduction in albuminuria and hematuria, and lowered GC-related toxicity, with an acceptable safety profile.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2751-2765"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Divergent Trends by Patient Age in Racial Disparities in Kidney Transplant Access","authors":"Jade Buford ,&nbsp;Jessica L. Harding ,&nbsp;Mengyu Di ,&nbsp;Marciana L. Laster ,&nbsp;Kelsey Drewry ,&nbsp;Stephen O. Pastan ,&nbsp;Rachel E. Patzer","doi":"10.1016/j.ekir.2025.05.045","DOIUrl":"10.1016/j.ekir.2025.05.045","url":null,"abstract":"<div><h3>Introduction</h3><div>Although non-Hispanic Black (Black) and non-Hispanic White (White) racial disparities in access to transplantation have decreased over the past 2 decades, it remains unclear whether trends are consistent across all ages and transplant steps.</div></div><div><h3>Methods</h3><div>We identified 1,091,206 White or Black adults initiating dialysis (cohort 1) and 226,703 adults waitlisted (cohort 2) in the United States Renal Data System (USRDS) from 2005 to 2019, followed through 2021. Study outcomes were as follows: (i) waitlisting (among patients on dialysis), (ii) living donor kidney transplant (LDKT) (among patients on dialysis), and (iii) deceased donor kidney transplant (DDKT) (among waitlisted adults). Individuals were grouped into eras (2005–2009, 2010–2014, and 2015–2019) based on dialysis initiation or waitlisting date. Multivariable-adjusted subdistribution hazard models assessed changes in racial disparities, overall and by age (18–29, 30–49, 50–64, and 65–80 years) at kidney replacement therapy (KRT) initiation.</div></div><div><h3>Results</h3><div>Racial disparities in waitlisting among patients on dialysis did not improve between 2005–2009 (0.90; 95% confidence interval [CI]: 0.88–0.92) and 2015–2019 (0.92; 95% CI: 0.90–0.94); <em>P</em> for interaction = 0.11). Among adults aged 18 to 29 years, relative rates of Black-White waitlisting differences worsened from 2005–2009 (0.77; 95% CI: 0.69–0.78) to 2015–2019 (0.68; 95% CI: 0.64–0.72); <em>P</em> = 0.13), whereas disparities among adults aged 30 to 49 years decreased (0.79 ; 95% CI: 0.76–0.81) to 0.89; (95% CI: 0.86–0.92; <em>P</em> &lt; 0.001). Among waitlisted adults, Black (vs. White patients) were less likely to receive a DDKT in 2005–2009 (0.92; 95% CI: 0.89–0.95) but more likely to receive a DDKT in 2015–2019 (1.28; 95% CI: 1.24–1.32); <em>P</em> &lt; 0.001). Black patients on dialysis were less likely to receive LDKT (0.37; 95% CI: 0.35–0.39); this trend persisted over time, with the largest and statistically significant decline among adults aged 65 to 80 years (0.49; 95% CI: 0.42–0.59) to 0.38; (95% CI: 0.33–0.45); <em>P</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>Strategies to improve access to transplantation, especially among younger and older Black adults, should be revisited.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2766-2777"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing the ADPKD-IFT140 Phenotypic Signature With Deep Learning and Advanced Imaging Biomarkers","authors":"Ahmad Ghanem ,&nbsp;Fadi George Munairdjy Debeh ,&nbsp;Abdul Hamid Borghol ,&nbsp;Nikola Zagorec ,&nbsp;Amanda L. Tapia ,&nbsp;Byron Smith ,&nbsp;Stefan Paul ,&nbsp;Abdul Basit ,&nbsp;Bassel AlKhatib ,&nbsp;Nay Nader ,&nbsp;Marie Therese Bou Antoun ,&nbsp;Adriana V. Gregory ,&nbsp;Hana Yang ,&nbsp;Rachel S. Schauer ,&nbsp;Neera K. Dahl ,&nbsp;Christian Hanna ,&nbsp;Vicente E. Torres ,&nbsp;Timothy L. Kline ,&nbsp;Peter C. Harris ,&nbsp;Emilie Cornec-Le Gall ,&nbsp;Fouad T. Chebib","doi":"10.1016/j.ekir.2025.04.062","DOIUrl":"10.1016/j.ekir.2025.04.062","url":null,"abstract":"<div><h3>Introduction</h3><div>ADPKD<em>-IFT140</em> is the third most common disease-causing variant in autosomal dominant polycystic kidney disease (ADPKD) after ADPKD-<em>PKD1</em> and ADPKD-<em>PKD2</em>. This study aimed to characterize the clinical presentation, progression, and distinctive imaging phenotype of ADPKD-<em>IFT140.</em></div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients with disease-causing variants in <em>IFT140</em>, nontruncating <em>PKD1</em> (<em>PKD1NT</em>), or <em>PKD2</em>. Patients were matched by sex (48.1% male), age (mean [SD]: 57.7 ± 13.3 years), and height-adjusted total kidney volume (TKV; htTKV) (median [Q1–Q3]: 572.9 [314.1–1137.9] ml/m). Two predictive models were developed in the development cohort <em>(n =</em> 81): a deep-learning model incorporating cyst-parenchymal surface area (CPSA) and cystic index, and a practical model using percentage of TKV_ellipsoid occupied by the 2 largest cysts, with cyst volumes estimated from cyst diameters using the formula <span><math><mrow><mi>V</mi><mo>=</mo><mfrac><mi>π</mi><mn>6</mn></mfrac><mspace></mspace><mrow><mo>(</mo><mrow><msubsup><mi>d</mi><mn>1</mn><mn>3</mn></msubsup><mo>+</mo><msubsup><mi>d</mi><mn>2</mn><mn>3</mn></msubsup></mrow><mo>)</mo></mrow></mrow></math></span>. Models were validated in an internal specificity cohort (<em>n</em> = 569) and an external sensitivity cohort (<em>n</em> = 36).</div></div><div><h3>Results</h3><div>Patients with ADPKD-<em>IFT140</em> exhibited fewer (median cyst number: 42) but larger cysts (average cyst volume: 12.1 ml), with 88.9% having no liver cysts, compared with ADPKD-<em>PKD1NT</em> and ADPKD-<em>PKD2</em>. The estimated glomerular filtration rate (eGFR) of decline was slower in ADPKD-<em>IFT140</em> (−0.69 ml/min per 1.73 m²/yr) than in ADPKD-<em>PKD1NT</em> (−1.62, <em>P</em> = 0.006) and in ADPKD-<em>PKD2</em> (−0.90, <em>P</em> = 0.737). The deep-learning model demonstrated an area-under-the-curve (AUC) of 0.949 for distinguishing ADPKD-<em>IFT140</em> patients in the development cohort, and 88.9% specificity in the internal cohort. A volume-to-TKV ratio ≥ 18.6% identified ADPKD-<em>IFT140</em> with an AUC of 0.814 and demonstrated 72.2% sensitivity in the external cohort.</div></div><div><h3>Conclusion</h3><div>We provide a detailed characterization of the ADPKD<em>-IFT140</em> phenotype that can be distinguished using a practical or deep-learning segmentation model applicable in diverse clinical settings.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2690-2707"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144756950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Transplant Outcomes in Recurrent Versus De Novo IgA Nephropathy","authors":"Mark Haas ,&nbsp;James Mirocha ,&nbsp;Hae Yoon Grace Choung ,&nbsp;Jean Hou ,&nbsp;Mercury Y. Lin ,&nbsp;Michifumi Yamashita ,&nbsp;Cynthia C. Nast","doi":"10.1016/j.ekir.2025.05.014","DOIUrl":"10.1016/j.ekir.2025.05.014","url":null,"abstract":"<div><h3>Introduction</h3><div>IgA nephropathy (IgAN) recurs frequently in kidney transplants, although the reported frequency of recurrence varies because many studies do not distinguish recurrent IgAN from IgAN occurring <em>de novo</em> in the allograft. In addition, there are only limited studies of graft outcomes in patients with recurrent IgAN.</div></div><div><h3>Methods</h3><div>We retrospectively examined 264 kidney transplant biopsies with glomerular IgA deposits, distinguishing whenever possible recurrent versus <em>de novo</em> IgAN, and compared clinical and pathologic features of biopsies of patients within these groups. We also examined graft outcomes in patients with available follow-up to identify findings associated with graft survival.</div></div><div><h3>Results</h3><div>A significantly greater fraction of biopsies with recurrent disease (<em>n</em> = 127) had mesangial (M1) and endocapillary (E1) hypercellularity, crescents (C1-2), and &gt; 1+ (0–4+ scale) glomerular C3 staining than biopsies with <em>de novo</em> (<em>n</em> = 46) IgAN; there was no significant difference between these groups with respect to Oxford S and T scores, or mean time posttransplantation of the biopsy. None of 19 biopsies with IgA deposits attributable to the donor had any MEST-C scores &gt; 0 or C3 staining &gt; 1+. Of 54 patients with recurrent IgAN and follow-up, 25 lost their grafts between 2 and 109 months postbiopsy. Findings at the time of biopsy significantly associated with an increased risk of graft loss in patients were higher serum creatinine (SCr) and proteinuria; Oxford E, T, and C scores &gt; 0; and C3 &gt; 1+.</div></div><div><h3>Conclusion</h3><div>The findings indicate the importance of measuring proteinuria in patients with suspected recurrent IgAN and scoring such biopsies using the Oxford MEST-C scores.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2659-2667"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome","authors":"Belen Requena ,&nbsp;Amir Shabaka ,&nbsp;Borja Lanzon ,&nbsp;Sara Martinez ,&nbsp;Isabel Galan Carrillo ,&nbsp;Teresa Bada-Bosch ,&nbsp;Angel Sevillano ,&nbsp;Ana Maria Tato-Ribera ,&nbsp;Coral Barbas ,&nbsp;Gema Medina-Gomez ,&nbsp;Carolina Gonzalez-Riano ,&nbsp;Gema Fernandez-Juarez","doi":"10.1016/j.ekir.2025.05.034","DOIUrl":"10.1016/j.ekir.2025.05.034","url":null,"abstract":"<div><h3>Introduction</h3><div>Alport syndrome (AS) is a hereditary kidney disease from <em>COL4A3–5</em> pathogenic variants causing glomerular basement membrane abnormalities. Although genetic and structural aspects are known, mechanisms linking collagen IV defects to podocyte injury are unclear. Lipotoxicity and lipid dysregulation likely mediate podocyte damage in AS, similar to diabetic kidney disease (DKD).</div></div><div><h3>Methods</h3><div>We sought to identify plasma and urine lipid alterations in autosomal dominant AS (ADAS) and X-linked AS (XLAS) compared with DKD and healthy controls. Using liquid chromatography coupled to mass spectrometry (MS), we annotated 580 and 203 lipid species in plasma and urine, respectively. Volcano plot and receiver operating characteristic (ROC) analyses (area under the curve [AUC] ≥ 0.80) were used to identify key lipids and highlight relevant lipotoxic pathways. Multivariate prediction of renal outcomes by specific lipid species was further performed.</div></div><div><h3>Results</h3><div>Compared with controls, AS exhibited unbalanced sphingolipid (SL) catabolism, ceramide (Cer) overload, and impaired fatty acid (FA) β-oxidation, alongside phospholipid and cholesterol imbalances suggestive of compromised isoform A1 of adenosine triphosphate–binding cassette transporter (ABCA1)-mediated lipid efflux and mitochondrial dysfunction. Comparisons with DKD indicated a shared lipotoxic environment with Cer elevation and disrupted FA metabolism. However, disease-specific adaptations emerged, with severe ABCA1 dysfunction and marked phospholipid or cholesterol derangements in DKD, whereas AS showed pronounced sphingomyelin (SM) depletion. Key lipids identified included urinary hexosylceramide (HexCer) 18:0(3O)/24:0(2OH) and acylcarnitine (CAR) 12:0. These findings were supported by multivariate prediction of renal outcomes by specific lipid species.</div></div><div><h3>Conclusion</h3><div>These findings demonstrate that AS involves distinct lipidomic disruptions and underscore shared lipotoxic mechanisms with DKD. This improved understanding of disease-specific lipid imbalances provides new potential therapeutic targets to mitigate podocyte injury and slow progression of AS.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2805-2820"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes","authors":"Liliana Italia De Rosa ,&nbsp;Martina Catania ,&nbsp;Kristiana Kola ,&nbsp;Michele Paolisi ,&nbsp;Pierpaolo Bianca ,&nbsp;Paolo Manunta ,&nbsp;Giuseppe Vezzoli ,&nbsp;Maria Teresa Sciarrone Alibrandi","doi":"10.1016/j.ekir.2025.03.059","DOIUrl":"10.1016/j.ekir.2025.03.059","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Page 2879"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis E Virus–Associated Endocapillary Proliferative Glomerulonephritis in an Immunocompetent Adult","authors":"Takanori Miyazaki ,&nbsp;Toshiyuki Hirai ,&nbsp;Hidenori Nishida ,&nbsp;Tetsurou Fujii ,&nbsp;Aya Isomura ,&nbsp;Kiyotaka Nagahama","doi":"10.1016/j.ekir.2025.06.028","DOIUrl":"10.1016/j.ekir.2025.06.028","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2871-2872"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}